Innate Pharma Partners With Sobi To Advance Lacutamab Toward Phase 3, Targets Accelerated Approval Filing In Sézary Syndrome

Innate Pharma SA

Innate Pharma SA

IPHA

0.00
  • Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndrome
  • Markus Jensen appointed Chief Medical Officer, bringing leadership continuity to execute TELLOMAK-3 and to prepare for upcoming IPH4502 development milestones
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.